x.com/DouglasYaoDY/status/2097377733466800489
1 correction found
Cobenfry
The recently approved schizophrenia drug is called COBENFY, not “Cobenfry.”
Full reasoning
The post names the comparison drug as “Cobenfry,” but the FDA-approved product is COBENFY (xanomeline and trospium chloride).
The FDA’s September 26, 2024 approval announcement says: “Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.” The manufacturer’s official site likewise identifies the product as COBENFY™.
This appears to be a naming error rather than a dispute about the drug itself, but the name in the post is still factually incorrect.
2 sources
- FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia | FDA
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
- COBENFY™ (xanomeline and trospium chloride) for Schizophrenia
What is COBENFY (co-BEN-fee)? COBENFY™ (xanomeline and trospium chloride) is a prescription medicine used to treat schizophrenia in adults.